The Coming Age of Flavonoids in the Treatment of Diabetic Complications.

dc.contributor.authorCaro-Ordieres, Teresa
dc.contributor.authorMarín-Royo, Gema
dc.contributor.authorOpazo-Ríos, Lucas
dc.contributor.authorJiménez-Castilla, Luna
dc.contributor.authorMoreno, Juan Antonio
dc.contributor.authorGómez-Guerrero, Carmen
dc.contributor.authorEgido, Jesús
dc.date.accessioned2025-01-07T17:18:47Z
dc.date.available2025-01-07T17:18:47Z
dc.date.issued2020-01-27
dc.description.abstractDiabetes mellitus (DM), and its micro and macrovascular complications, is one of the biggest challenges for world public health. Despite overall improvement in prevention, diagnosis and treatment, its incidence is expected to continue increasing over the next years. Nowadays, finding therapies to prevent or retard the progression of diabetic complications remains an unmet need due to the complexity of mechanisms involved, which include inflammation, oxidative stress and angiogenesis, among others. Flavonoids are natural antioxidant compounds that have been shown to possess anti-diabetic properties. Moreover, increasing scientific evidence has demonstrated their potential anti-inflammatory and anti-oxidant effects. Consequently, the use of these compounds as anti-diabetic drugs has generated growing interest, as is reflected in the numerous in vitro and in vivo studies related to this field. Therefore, the aim of this review is to assess the recent pre-clinical and clinical research about the potential effect of flavonoids in the amelioration of diabetic complications. In brief, we provide updated information concerning the discrepancy between the numerous experimental studies supporting the efficacy of flavonoids on diabetic complications and the lack of appropriate and well-designed clinical trials. Due to the well-described beneficial effects on different mechanisms involved in diabetic complications, the excellent tolerability and low cost, future randomized controlled studies with compounds that have adequate bioavailability should be evaluated as add-on therapy on well-established anti-diabetic drugs.
dc.identifier.doi10.3390/jcm9020346
dc.identifier.issn2077-0383
dc.identifier.pmcPMC7074336
dc.identifier.pmid32012726
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7074336/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2077-0383/9/2/346/pdf?version=1583042385
dc.identifier.urihttps://hdl.handle.net/10668/28315
dc.issue.number2
dc.journal.titleJournal of clinical medicine
dc.journal.titleabbreviationJ Clin Med
dc.language.isoen
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectcardiovascular disease
dc.subjectdiabetes
dc.subjectdiabetic nephropathy
dc.subjectflavonoids
dc.subjectinflammation
dc.subjectmicrovascular complications
dc.subjectoxidative stress
dc.subjecttherapeutics
dc.titleThe Coming Age of Flavonoids in the Treatment of Diabetic Complications.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number9

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC7074336.pdf
Size:
1.54 MB
Format:
Adobe Portable Document Format